# Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

> **NCT00537030** · NA · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 59 (actual)

## Conditions studied

- Adult Acute Lymphoblastic Leukemia
- Childhood Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Asparaginase
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT00537030
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-11
- **Primary completion:** 2011-02-01
- **Final completion:** —
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2019-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537030, "Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00537030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*